Regen Biopharma subsidiary KCL receives USPTO patent grant for NR2F6 inhibition cancer therapy

Regen BioPharma Inc

KCL Therapeutics (Regen Biopharma subsidiary) granted USPTO patent for NR2F6 inhibition method.
Invention pertains to generating IL-17 antitumor effector cells by inhibiting NR2F6.
NR2F6 described as an immune checkpoint and cancer stem cell differentiator.

item 8.01

Regen BioPharma Inc filing history →

Source: SEC EDGAR

accession 0001607062-21-000187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.